Quark Pharmaceuticals, Inc.
Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Pharmaceuticals is interested in. The drug development company is using cutting-edge RNA interference (RNAi) technology to develop small-interfering RNA (siRNA) molecules, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Pharmaceuticals is developing other candidates for ailments such as acute renal (kidney) failure, hearing loss, and dyslipidemia (a metabolic syndrome).
Contact Details
Executives
Chairman
Philip B. Simon
President, CEO, and Director
Daniel Zurr